ADCE-T02: A Next-generation Antibody-Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability.
Thomas T Poulsen, Olga Ilina, Jonathan H Wardman...
https://pubmed.ncbi.nlm.nih.gov/41996633/Actively Recruiting
Led by Adcendo ApS · Updated on 2026-09-09
210
Participants Needed
14
Research Sites
13 weeks
Total Duration
Researchers are evaluating ADCE-T02, an investigational tissue factor targeted antibody-drug conjugate, in adults with advanced solid tumors including head and neck squamous cell carcinoma HNSCC and pancreatic ductal adenocarcinoma PDAC. This phase 1 study aims to find the maximum tolerated dose, recommended dose, and assess the safety and tolerability of ADCE-T02 when given alone. The study includes patients who have progressed after at least one systemic therapy. Participants receive ADCE-T02 intravenously at different dose levels to determine the optimal dose for further studies. The trial includes a dose escalation phase followed by an expansion phase for specific tumor types. Treatment is given as a single therapy, and dosing schedules vary to assess safety and effects. During the study, participants undergo regular assessments including measurement of tumor response using RECIST criteria, monitoring for adverse events, and laboratory tests to evaluate organ function and drug levels. Researchers will track outcomes such as overall response rate, disease control, progression-free survival, and presence of anti-drug antibodies for up to 24 months. Safety and tolerability are closely monitored throughout the study duration.
CONDITIONS
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
S
Sherri Paxton
S
Sarah Berardini
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Adcendo ApS
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | ADCE‑T02 (investigational) | Usual systemic therapy (context) |
|---|---|---|
| What it is | ADCE‑T02 is a tissue‑factor‑targeted antibody‑drug conjugate being evaluated in a dose‑escalation Phase I trial for unresectable advanced solid tumors | Patients progressing after prior therapy typically receive standard systemic treatments such as chemotherapy, targeted therapy, or immunotherapy depending on tumor type and prior regimens |
| Role in trial | Investigational monotherapy evaluated in first‑in‑human dose‑escalation followed by expansion cohorts | Not part of the study; represents typical care outside trial |
| Primary use | Develop the maximum tolerated dose and recommended expansion phase dose; assess safety and tolerability | Management of disease progression with systemic therapies tailored to cancer subtype and prior treatment history |
| How it is given or performed | Administered by intravenous infusion in escalating dose cohorts | Systemic therapies are given according to regimen: intravenously, orally, or by infusion depending on agent |
| Evidence status | Only preclinical or early phase clinical data exists; safety and dose‑finding ongoing | Standard systemic regimens have established efficacy in prolonging life or controlling disease depending on tumor type |
| Important risks | Potential risks are under evaluation; ADC class may involve off‑target effects such as cytotoxicity, ocular toxicity, or coagulation effects although ADCE‑T02 design aims to reduce coagulation interference | Risks vary by agent class; systemic chemotherapies, targeted therapies, or immunotherapies are associated with known toxicities managed per clinical protocols |
| Important limitations | Early‑phase design limits conclusions about efficacy or long‑term safety; no comparator arm to measure benefit | Treatment choices depend on tumor subtype, prior lines of therapy, biomarker status, and patient performance, leading to variable outcomes |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants receive intravenous ADCE-T02 at varying dose levels to evaluate safety, determine the maximum tolerated dose, and recommended dose.
Visits as scheduled during treatment
Duration - Up to 24 months
Participants are monitored for safety, side effects, and treatment response including tumor assessments and laboratory tests.
Regular visits and assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Thomas T Poulsen, Olga Ilina, Jonathan H Wardman...
https://pubmed.ncbi.nlm.nih.gov/41996633/Adcendo ApS
Lead Sponsor